Regulation and targets of receptor tyrosine kinases.

Ligand-mediated activation of receptor tyrosine kinases (RTKs) results in autophosphorylation of both the receptor catalytic domain and noncatalytic regions of the cytoplasmic domain. Catalytic domain phosphorylation leads to activation and potentiation of receptor kinase activity. Noncatalytic domain phosphorylation creates docking sites for downstream cytoplasmic targets, which bind to specific receptor phosphotyrosine residues. Downstream signaling pathways are constructed in a modular fashion. In addition to SH2 and PTB (phosphotyrosine binding) domains, downstream signal proteins also contain domains that recognize other protein and phospholipid motifs. The arrangement and re-arrangement of various combinations of modular domains in different signaling proteins (combinatorial use) has allowed for the creation of complex signaling networks and pathways. In addition to performing catalytic functions, signaling proteins serve as scaffolds for the assembly of multiprotein signaling complexes, as adaptors, as transcription factors and as signal pathway regulators. Recent results show that the juxtamembrane region of Eph receptors is important in receptor autoregulation. Mutations in the juxtamembrane region of several RTKs have been shown to play a role in oncogenesis. It is likely that dysregulation of other modular components of signaling pathways also plays a role in oncogenic transformation.

[1]  T Pawson,et al.  SH2 domains, interaction modules and cellular wiring. , 2001, Trends in cell biology.

[2]  Tony Pawson,et al.  Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication , 2001, Nature.

[3]  T. Pawson,et al.  Signaling through scaffold, anchoring, and adaptor proteins. , 1997, Science.

[4]  W. Langdon,et al.  Cbl: many adaptations to regulate protein tyrosine kinases , 2001, Nature Reviews Molecular Cell Biology.

[5]  S. Hubbard,et al.  Crystallographic and Solution Studies of an Activation Loop Mutant of the Insulin Receptor Tyrosine Kinase , 2001, The Journal of Biological Chemistry.

[6]  T. Pawson,et al.  The crystal structure of an Eph receptor SAM domain reveals a mechanism for modular dimerization , 1999, Nature Structural Biology.

[7]  T. Pawson,et al.  Phosphorylation of Tyrosine Residues in the Kinase Domain and Juxtamembrane Region Regulates the Biological and Catalytic Activities of Eph Receptors , 2000, Molecular and Cellular Biology.

[8]  Y. Ma,et al.  Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. , 2001, Leukemia research.

[9]  T. Pawson,et al.  ShcA and Grb2 mediate polyoma middle T antigen‐induced endothelial transformation and Gab1 tyrosine phosphorylation , 2001, The EMBO journal.

[10]  S. Hubbard,et al.  Protein tyrosine kinase structure and function. , 2000, Annual review of biochemistry.

[11]  T. Pawson,et al.  Regulation of SLAM-mediated signal transduction by SAP, the X-linked lymphoproliferative gene product , 2001, Nature Immunology.

[12]  J. Melo,et al.  The molecular biology of chronic myeloid leukemia. , 2000, Blood.

[13]  T. Hunter,et al.  Signaling—2000 and Beyond , 2000, Cell.

[14]  J. Fletcher,et al.  KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. , 2000, The American journal of pathology.

[15]  T Pawson,et al.  Bcr‐Abl oncoproteins bind directly to activators of the Ras signalling pathway. , 1994, The EMBO journal.

[16]  T. Pawson,et al.  Protein-protein interactions define specificity in signal transduction. , 2000, Genes & development.

[17]  Tony Pawson,et al.  The Shc adaptor protein is highly phosphorylated at conserved, twin tyrosine residues (Y239/240) that mediate protein–protein interactions , 1996, Current Biology.

[18]  E. Wagner,et al.  Embryonic lethalities and endothelial tumors in chimeric mice expressing polyoma virus middle T oncogene , 1988, Cell.

[19]  F. Diella,et al.  Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. , 1999, Genes & development.

[20]  G. Krystal,et al.  Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. , 1996, Cancer research.

[21]  T. Pawson,et al.  Structural Basis for Autoinhibition of the EphB2 Receptor Tyrosine Kinase by the Unphosphorylated Juxtamembrane Region , 2001, Cell.

[22]  T Pawson,et al.  The ShcA phosphotyrosine docking protein sensitizes cardiovascular signaling in the mouse embryo. , 2000, Genes & development.

[23]  Tony Pawson,et al.  Gene dosage-dependent functions for phosphotyrosine-Grb2 signaling during mammalian tissue morphogenesis , 2001, Current Biology.

[24]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[25]  A. Kazlauskas,et al.  Full Activation of the Platelet-derived Growth Factor β-Receptor Kinase Involves Multiple Events* , 1998, The Journal of Biological Chemistry.

[26]  E. Pasquale,et al.  Eph receptors and ephrin ligands: embryogenesis to tumorigenesis , 2000, Oncogene.